(Q36717952)

15 August 2017

1 reference

title

Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists (English)

1 reference

15 August 2017

0 references

1 reference

3

Daniel Batlle

1 reference

15 August 2017

Sheldon Chen

1

1 reference

15 August 2017

Nishant Jalandhara

series ordinal

2

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

82-95

1 reference

Hyponatremia in the intensive care: from diagnosis to treatment

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

Myelinolysis after correction of hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

Antidiuretic hormone. Normal and disordered function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Systemic diseases associated with disorders of water homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Hyponatremia in intracranial disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Evaluation and management of hypo-osmolality in hospitalized patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Hyponatremia and hypernatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Cost of illness of hyponatremia in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

The syndrome of inappropriate antidiuretic hormone secretion

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Hyponatremia in patients with central nervous system disease: SIADH versus CSW

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Hyponatremic emergencies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

1 reference

7 January 2021

The pathophysiology and treatment of hyponatraemic encephalopathy: an update

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Epidemiology, pathophysiology, and management of hyponatremic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Hyponatremia in critically ill neurological patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Cerebral salt wasting syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

New approach to disturbances in the plasma sodium concentration

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Treatment of hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Treatment of symptomatic hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Superiority of Demeclocycline over Lithium in the Treatment of Chronic Syndrome of Inappropriate Secretion of Antidiuretic Hormone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Therapeutic approach to hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Central and extrapontine myelinolysis: then...and now.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin V2 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin V2 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin antagonism in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

The clinical effects of vasopressin receptor antagonists in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0401

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0401

1 reference

15 August 2017

1 reference